Lab
Quest Diagnostics of Pennsylvania INC.
Quest Diagnostics of Pennsylvania INC. was paid $492K by Medicaid between Jan 2018 and Sep 2019, across 34 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 39% of everything it billed.
33Billing provider infoQUEST DIAGNOSTICS OF PENNSYLVANIA INC.
NORTH SYRACUSE, NY 13212
NORTH SYRACUSE, NY 13212
33aNPI1336167964assigned 07/18/2006
33bProvider typeClinical Medical Laboratory
28Total paid$492K
24GClaims11,919
24DCodes billed34
24AFirst – last monthJan 2018 – Sep 2019
Compared with peers
Next to other Clinical Medical Laboratory providers in New York
Rank by total paid#62 of 116
Median peer was paid$618K
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,847 | $291K | |
| 2019 | 4,072 | $201K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 39% | 3,079 | 2,204 | $193K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 34% | 2,692 | 1,918 | $169K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 4.7% | 239 | 211 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.7% | 508 | 503 | $18K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.7% | 503 | 498 | $18K |
| 80050 | General health panel | 2.0% | 349 | 341 | $10K |
| 80061 | Lipid panel | 1.4% | 521 | 516 | $7K |
| 80053 | Comprehensive metabolic panel | 1.1% | 563 | 541 | $6K |
| 87510 | 1.1% | 268 | 266 | $6K | |
| 87480 | 1.1% | 268 | 266 | $6K | |
| 87660 | 1.1% | 265 | 263 | $5K | |
| 80074 | <1% | 88 | 88 | $4K |
22 more codes
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 253 | $4K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 435 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 91 | $3K |
| 87631 | <1% | 12 | $2K | |
| 86803 | <1% | 161 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 171 | $1K |
| 84439 | <1% | 136 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 28 | $1K |
| 86704 | <1% | 82 | $1K | |
| 86592 | <1% | 336 | $999.62 | |
| 86706 | <1% | 84 | $934.58 | |
| 86708 | <1% | 73 | $934.56 | |
| 81001 | <1% | 236 | $766.92 | |
| 87340 | <1% | 71 | $757.40 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 27 | $622.08 |
| 82607 | <1% | 39 | $569.80 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 57 | $518.67 |
| 82043 | <1% | 93 | $514.28 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 16 | $466.95 |
| 82570 | <1% | 106 | $448.84 | |
| 87088 | <1% | 45 | $364.64 | |
| 87070 | <1% | 24 | $207.46 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOWLES, CHARLES (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.